7 days ago
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter.
Robot developer Vicarious Surgical, which raised more than $425 million from investors including Bill Gates before its 2021 initial public offering, has obtained approval from shareholders to wind down and liquidate the business.
Shareholders voted at a special meeting Tuesday to enter into an ******* ignment for the benefit of creditors, an alternative to bankruptcy. The process transfers a company's ******* ets into a trust for distribution to creditors.
Vicarious was working to develop a single-port surgical robot that "shrinks the surgeon" to perform procedures inside the patient's abdomen but faced a series of delays in bringing the device to market and last year canceled plans for a clinical trial as it pushed to finish the design for the commercial version of the system.
Vicarious is shutting down 12 years after it was formed with the ambitious goals of improving patient outcomes, increasing surgical efficiency and addressing what its founders saw as significant limitations to legacy robotic platforms. Its 2021 merger with D8 Holdings, a special purpose acquisition company, or ******* , valued the company at $1.1 billion.
#medtech #shareholders #down #special
Robot developer Vicarious Surgical, which raised more than $425 million from investors including Bill Gates before its 2021 initial public offering, has obtained approval from shareholders to wind down and liquidate the business.
Shareholders voted at a special meeting Tuesday to enter into an ******* ignment for the benefit of creditors, an alternative to bankruptcy. The process transfers a company's ******* ets into a trust for distribution to creditors.
Vicarious was working to develop a single-port surgical robot that "shrinks the surgeon" to perform procedures inside the patient's abdomen but faced a series of delays in bringing the device to market and last year canceled plans for a clinical trial as it pushed to finish the design for the commercial version of the system.
Vicarious is shutting down 12 years after it was formed with the ambitious goals of improving patient outcomes, increasing surgical efficiency and addressing what its founders saw as significant limitations to legacy robotic platforms. Its 2021 merger with D8 Holdings, a special purpose acquisition company, or ******* , valued the company at $1.1 billion.
#medtech #shareholders #down #special
14 days ago
Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the 8 Worst Blue Chip Stocks to Buy Now.
On July 9, 2026, BMO Capital ****** yst Vik Chopra initiated coverage of Intuitive Surgical, Inc. (NASDAQ:ISRG) with an Outperform rating and $518 price target. Chopra said the da Vinci 5 upgrade cycle remains in the early innings, procedure growth is broadening into new specialties and geographies, and the earnings stream is "durable and visible."
On July 6, Evercore ISI lowered the firm's price target on Intuitive Surgical to $430 from $480 and kept an In Line rating on the shares. Evercore ISI said its Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector.
Last month, BofA ****** yst Travis Steed lowered the firm's price target on Intuitive Surgical to $515 from $520 and kept a Buy rating on the shares. Steed noted that BofA's services team continues to highlight a lower utilization environment and took a more conservative view on 2027 medtech company estimates, given that valuations already reflect utilization risk. Steed also ****** umed inflation will be more of a headwind in 2027, with less margin expansion for medtech, and lowered 2027 estimates across the firm's larger-cap coverage with exposure to utilization and inflation.
Intuitive Surgical, Inc. (NASDAQ:ISRG) develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.
On July 9, 2026, BMO Capital ****** yst Vik Chopra initiated coverage of Intuitive Surgical, Inc. (NASDAQ:ISRG) with an Outperform rating and $518 price target. Chopra said the da Vinci 5 upgrade cycle remains in the early innings, procedure growth is broadening into new specialties and geographies, and the earnings stream is "durable and visible."
On July 6, Evercore ISI lowered the firm's price target on Intuitive Surgical to $430 from $480 and kept an In Line rating on the shares. Evercore ISI said its Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector.
Last month, BofA ****** yst Travis Steed lowered the firm's price target on Intuitive Surgical to $515 from $520 and kept a Buy rating on the shares. Steed noted that BofA's services team continues to highlight a lower utilization environment and took a more conservative view on 2027 medtech company estimates, given that valuations already reflect utilization risk. Steed also ****** umed inflation will be more of a headwind in 2027, with less margin expansion for medtech, and lowered 2027 estimates across the firm's larger-cap coverage with exposure to utilization and inflation.
Intuitive Surgical, Inc. (NASDAQ:ISRG) develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.
15 days ago
Intuitive Surgical (ISRG) stock tumbled Tuesday, alongside shares of other medtech leaders like Abbott Laboratories (ABT), Stryker (SYK) and Medtronic (MDT), after HCA Healthcare trimmed its full-year earnings outlook, suggesting a drop in surgical procedures.
HCA Healthcare, the largest for-profit hospital operator, said inpatient surgeries declined 2.3% while outpatient procedures fell 3.4% in the second quarter compared with the year-ago period.
As a result, HCA now projects $6.3 billion to $6.7 billion in net income and adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA, of $15.4 billion to $16.1 billion. That's down from the prior outlook for roughly $6.5 billion to $7.04 billion in net income and adjusted EBITDA of $15.55 billion to $16.45 billion.
HCA also narrowed its sales guidance, now projecting $77 billion to $79.5 billion. The midpoint of the new outlook, $78.25 billion, matches the company's prior view.
HCA Healthcare, the largest for-profit hospital operator, said inpatient surgeries declined 2.3% while outpatient procedures fell 3.4% in the second quarter compared with the year-ago period.
As a result, HCA now projects $6.3 billion to $6.7 billion in net income and adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA, of $15.4 billion to $16.1 billion. That's down from the prior outlook for roughly $6.5 billion to $7.04 billion in net income and adjusted EBITDA of $15.55 billion to $16.45 billion.
HCA also narrowed its sales guidance, now projecting $77 billion to $79.5 billion. The midpoint of the new outlook, $78.25 billion, matches the company's prior view.
16 days ago
Abbott Laboratories (NYSE:ABT) is one of the Best Monopoly Stocks to Buy According to Hedge Funds. On June 30, Baird initiated coverage on the company's stock with an "Outperform" rating, setting a price objective of $121.00. The firm sees Abbott Laboratories (NYSE:ABT)'s portfolio as delivering steady top-line and earnings growth over the upcoming several years. As per the firm, the company's medical device segment is expected to see an above-peer growth trajectory.
The company's diagnostics, nutrition, and established pharmaceutical offerings enhance Abbott Laboratories (NYSE:ABT)'s reach throughout the healthcare spectrum. As per the firm, there is a clearer path to upside in FY 2027 and FY 2028, with new products and indication opportunities layering in, and Exact Sciences integration and synergies contributing to the results.
In a different update, Evercore ISI **** yst Vijay **** ar reduced the firm's price objective on Abbott Laboratories (NYSE:ABT)'s stock to $112 from $120 and maintained an "Outperform" rating. The firm's Q2 preview for MedTech, Life Sciences Tools, and Diagnostics demonstrates healthy procedure volumes as well as capex trends throughout the sector.
Abbott Laboratories (NYSE:ABT) is engaged in discovering, developing, manufacturing, and selling health care products.
While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
The company's diagnostics, nutrition, and established pharmaceutical offerings enhance Abbott Laboratories (NYSE:ABT)'s reach throughout the healthcare spectrum. As per the firm, there is a clearer path to upside in FY 2027 and FY 2028, with new products and indication opportunities layering in, and Exact Sciences integration and synergies contributing to the results.
In a different update, Evercore ISI **** yst Vijay **** ar reduced the firm's price objective on Abbott Laboratories (NYSE:ABT)'s stock to $112 from $120 and maintained an "Outperform" rating. The firm's Q2 preview for MedTech, Life Sciences Tools, and Diagnostics demonstrates healthy procedure volumes as well as capex trends throughout the sector.
Abbott Laboratories (NYSE:ABT) is engaged in discovering, developing, manufacturing, and selling health care products.
While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
27 days ago
Johnson & Johnson (NYSE:JNJ) is one of billionaire Cliff Asness' top 10 healthcare stock picks. On June 25, Johnson & Johnson (NYSE:JNJ) announced the commercial launch of the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform in Europe. That means the platform is now commercially available to electrophysiologists across the EMEA region for the treatment of cardiac arrhythmias, including atrial fibrillation.
Copyright: moovstock / 123RF Stock Photo
The company said that the platform is the first of its kind to combine two distinct energy sources in a single catheter-based solution. It combines radiofrequency (RF) and pulsed field (PF) energy to allow physicians to switch between the two during the same procedure without having to change equipment. This is clinically significant because RF and PF ablation each have different tissue effects and safety profiles, said Nicolas Derval, M.D., a consultant for Johnson & Johnson based in Bordeaux, France. Derval added that the ability to use both gives doctors more flexibility to tailor treatment to individual patient anatomy and disease patterns.
Johnson & Johnson explained that the platform consists of the DE STSF Catheter, which is an irrigated, contact-force sensing catheter that physically delivers energy to heart tissue. The other half consists of the TRUPULSE Generator, which controls and powers the delivery of both RF and PF energy. The company said the system is fully integrated with its CARTO 3 System, which is an electro-anatomical mapping platform. This combination enables real-time 3D visualization, contact-force feedback, and index-guided ablation during live procedures.
Johnson & Johnson (NYSE:JNJ) is a healthcare conglomerate. It operates through two segments: Innovative Medicine, which develops and markets prescription drugs in oncology, immunology, neuroscience, and infectious disease, and MedTech, which manufactures medical devices for surgery, orthopedics, and interventional solutions.
Copyright: moovstock / 123RF Stock Photo
The company said that the platform is the first of its kind to combine two distinct energy sources in a single catheter-based solution. It combines radiofrequency (RF) and pulsed field (PF) energy to allow physicians to switch between the two during the same procedure without having to change equipment. This is clinically significant because RF and PF ablation each have different tissue effects and safety profiles, said Nicolas Derval, M.D., a consultant for Johnson & Johnson based in Bordeaux, France. Derval added that the ability to use both gives doctors more flexibility to tailor treatment to individual patient anatomy and disease patterns.
Johnson & Johnson explained that the platform consists of the DE STSF Catheter, which is an irrigated, contact-force sensing catheter that physically delivers energy to heart tissue. The other half consists of the TRUPULSE Generator, which controls and powers the delivery of both RF and PF energy. The company said the system is fully integrated with its CARTO 3 System, which is an electro-anatomical mapping platform. This combination enables real-time 3D visualization, contact-force feedback, and index-guided ablation during live procedures.
Johnson & Johnson (NYSE:JNJ) is a healthcare conglomerate. It operates through two segments: Innovative Medicine, which develops and markets prescription drugs in oncology, immunology, neuroscience, and infectious disease, and MedTech, which manufactures medical devices for surgery, orthopedics, and interventional solutions.
27 days ago
Intuitive Surgical, Inc. (NASDAQ:ISRG) has declined more than 29% over the past 6 months and is now trading close to its 52-week lows. The downward pressure stems from regulatory scrutiny regarding instrument reuse and concerns over Chinese competition.
However, the Street expects the stock to rebound, with ******* ysts' 12-month average price target suggesting more than 42% upside, making Intuitive Surgical, Inc. (NASDAQ:ISRG) one of the Top Large Cap Stocks to Invest In At 52-Week Lows.
Recently, on June 23, BTIG ******* yst Ryan Zimmerman reiterated a Buy rating on the stock with a price target of $574. Earlier on June 12, Bank of America Securities had reiterated a Buy rating on the stock with a price target of $515, down slightly from the previous target of $520. The adjustment reflects a more cautious stance on 2027 estimates across BofA's broader medtech coverage.
BofA noted that its services team has flagged a lower utilization environment, suggesting hospitals and surgical centers are using robotic surgery systems less intensively than previously expected. Moreover, the firm's ******* yst Steed also noted that factoring in inflation as a growing headwind in 2027, with less room for margin expansion across the medtech sector.
Intuitive Surgical Inc. (NASDAQ:ISRG) engages in the development, manufacturing, and marketing of da Vinci surgical systems and Ion endoluminal system.
However, the Street expects the stock to rebound, with ******* ysts' 12-month average price target suggesting more than 42% upside, making Intuitive Surgical, Inc. (NASDAQ:ISRG) one of the Top Large Cap Stocks to Invest In At 52-Week Lows.
Recently, on June 23, BTIG ******* yst Ryan Zimmerman reiterated a Buy rating on the stock with a price target of $574. Earlier on June 12, Bank of America Securities had reiterated a Buy rating on the stock with a price target of $515, down slightly from the previous target of $520. The adjustment reflects a more cautious stance on 2027 estimates across BofA's broader medtech coverage.
BofA noted that its services team has flagged a lower utilization environment, suggesting hospitals and surgical centers are using robotic surgery systems less intensively than previously expected. Moreover, the firm's ******* yst Steed also noted that factoring in inflation as a growing headwind in 2027, with less room for margin expansion across the medtech sector.
Intuitive Surgical Inc. (NASDAQ:ISRG) engages in the development, manufacturing, and marketing of da Vinci surgical systems and Ion endoluminal system.
1 month ago
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm's services team continues to highlight a lower utilization environment, and Barclays wants to take a more conservative view on 2027 medtech company estimates, given valuations are already reflecting utilization risk. It further told investors that the firm is lowering 2027 estimates across its larger-cap coverage where there's exposure to utilization and inflation.
Boston Scientific Corporation (NYSE:BSX) also received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated its model on the stock to take into account slowdowns in the U.S. Watchman business in 2026 and 2027, which have negative implications on its revenue and EPS estimates.
Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Boston Scientific Corporation (NYSE:BSX) also received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated its model on the stock to take into account slowdowns in the U.S. Watchman business in 2026 and 2027, which have negative implications on its revenue and EPS estimates.
Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
1 month ago
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm's services team continues to highlight a lower utilization environment, and Barclays wants to take a more conservative view on 2027 medtech company estimates, given valuations are already reflecting utilization risk. It further told investors that the firm is lowering 2027 estimates across its larger-cap coverage where there's exposure to utilization and inflation.
Boston Scientific Corporation (NYSE:BSX) also received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated its model on the stock to take into account slowdowns in the U.S. Watchman business in 2026 and 2027, which have negative implications on its revenue and EPS estimates.
Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Boston Scientific Corporation (NYSE:BSX) also received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated its model on the stock to take into account slowdowns in the U.S. Watchman business in 2026 and 2027, which have negative implications on its revenue and EPS estimates.
Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
1 month ago
With a market cap of $580.1 billion, Johnson & Johnson (JNJ) is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of medical products and solutions through its Innovative Medicine and MedTech segments. It serves healthcare providers, hospitals, retailers, and patients worldwide across areas including pharmaceuticals, surgery, orthopedics, cardiovascular care, and vision health.
The New Brunswick, New Jersey-based company is expected to unveil its fiscal Q2 2026 results before the market opens on Wednesday, Jul. 15. Ahead of the event, ****** ysts forecast JNJ to post an adjusted EPS of $2.83, a growth of 2.2% from $2.77 in the same quarter last year. It has surpassed Wall Street's bottom-line projections in the past four quarters.
Palantir Stock Crashes to a 52-Week Low: Why It's Time to Buy the Dip.
Corning Stock Skyrockets on AI-Related Demand, Spurring Unusual Call Option Buying
AMD's MEXT Acquisition Is More Important Than Markets Realize. Here's How It Solves the Memory Bottleneck.
The New Brunswick, New Jersey-based company is expected to unveil its fiscal Q2 2026 results before the market opens on Wednesday, Jul. 15. Ahead of the event, ****** ysts forecast JNJ to post an adjusted EPS of $2.83, a growth of 2.2% from $2.77 in the same quarter last year. It has surpassed Wall Street's bottom-line projections in the past four quarters.
Palantir Stock Crashes to a 52-Week Low: Why It's Time to Buy the Dip.
Corning Stock Skyrockets on AI-Related Demand, Spurring Unusual Call Option Buying
AMD's MEXT Acquisition Is More Important Than Markets Realize. Here's How It Solves the Memory Bottleneck.
1 yr. ago
News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: https://ow.ly/KKEz50TTwo6.
Unlock expert ****** ysis of the pharma, biotech, medtech, and consumer health with 1-week’s access to our award-winning publications.
Unlock expert ****** ysis of the pharma, biotech, medtech, and consumer health with 1-week’s access to our award-winning publications.
1 yr. ago
Wonderful news,
JNJMedTech
JNJNews
JNJInnovation
we have some excellent imaging enterprise portfolio **** ets on our official business networks.
_smartgxp
Thanks
JNJMedTech
JNJNews
JNJInnovation
we have some excellent imaging enterprise portfolio **** ets on our official business networks.
_smartgxp
Thanks
